HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agrawal, L. Articles by Alkhatib, G. Search for Related Content PubMed PubMed Citation Articles by Agrawal, L. Articles by Alkhatib, G.

(Journal of Leukocyte Biology. 2002;72:1063-1074.)
© 2002 by Society for Leukocyte Biology

Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs)

Department of Microbiology and Immunology and Walther Oncology Center, Indiana University School of Medicine; and The Walther Cancer Institute, Indianapolis, IN

Correspondence: Ghalib Alkhatib, Department of Microbiology and Immunology and Walther Oncology Center, Indiana University School of Medicine, 635 Barnhill Drive, Room 420, Indianapolis, IN 46202. E-mail: galkhati{at}iupui.edu

Although a number of chemokine receptors display coreceptor activities in vitro, chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) remain the major coreceptors used by the human immunodeficiency virus type 1 (HIV-1). In this study, we used an envelope-mediated fusion assay to demonstrate low CCR4 coreceptor activity with some primary HIV-1 and simian immunodeficiency virus-1 (mac316) isolates in vitro. The coreceptor activity was sensitive to CCR4-specific antibodies and to the CCR4-specific chemokine ligand macrophage-derived chemokine (MDC)/chemokine ligand 22 (CCL22). Treatment of peripheral blood mononuclear cells (PBMCs; which express high levels of CCR4) with CCL22 caused down-modulation of endogenous CCR4 but had no significant effect on HIV-1 entry, suggesting that CCR4 may not be used as an entry coreceptor. Despite expression of other minor coreceptors on PBMCs, CCR5 and CXCR4 are preferentially used by HIV-1 isolates, as shown by chemokine-inhibition data. To determine the factors involved in this selective use, we analyzed CCR4 coreceptor activity and compared it with CCR5 use in PBMCs. We used a quantitative fluorescence-activated cell-sorting assay to estimate the numbers of CCR4 and CCR5 antibody-binding sites (ABS) on PBMCs. Although CCR4 was found on a higher percentage of CD4(+) cells, CCR5 ABS was twofold greater than CCR4 ABS on CD4(+) cells. Confocal microscopy revealed strong cell-surface CD4/CCR5 but weak CD4/CCR4 colocalization in PBMCs. Binding studies demonstrated that soluble gp120 had greater affinity to CCR5 than CCR4. The results suggested that coreceptor density, colocalization with CD4, and affinity of the viral gp120 to the coreceptor may determine preferential coreceptor use by HIV-1.

Key Words: (MDC) • CCRA • coreceptors • HIV-1 • PBMCs • macrophage-derived chemokine

This article has been cited by other articles:

				D. R. Dewin, J. Catusse, and U. A. Gompels Identification and Characterization of U83A Viral Chemokine, a Broad and Potent {beta}-Chemokine Agonist for Human CCRs with Unique Selectivity and Inhibition by Spliced Isoform J. Immunol., January 1, 2006; 176(1): 544 - 556. [Abstract] [Full Text] [PDF]

				S. F. Abdelwahab, F. Cocchi, K. C. Bagley, R. Kamin-Lewis, R. C. Gallo, A. DeVico, and G. K. Lewis HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses PNAS, December 9, 2003; 100(25): 15006 - 15010. [Abstract] [Full Text] [PDF]